HC Wainwright Cuts PDS Biotechnology (NASDAQ:PDSB) Price Target to $13.00

PDS Biotechnology (NASDAQ:PDSB) had its target price trimmed by HC Wainwright from $21.00 to $13.00 in a research note published on Thursday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

PDS Biotechnology Stock Performance

PDSB opened at $1.26 on Thursday. PDS Biotechnology has a fifty-two week low of $1.13 and a fifty-two week high of $4.42. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.84 and a current ratio of 2.84. The company has a fifty day moving average of $1.40 and a 200 day moving average of $2.15. The stock has a market capitalization of $48.12 million, a price-to-earnings ratio of -1.09 and a beta of 1.68.

PDS Biotechnology (NASDAQ:PDSB) last posted its earnings results on Thursday, March 27th. The company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.08. As a group, sell-side analysts forecast that PDS Biotechnology will post -1.2 earnings per share for the current fiscal year.

Institutional Investors Weigh In On PDS Biotechnology

Institutional investors have recently made changes to their positions in the company. Marshall Wace LLP grew its holdings in shares of PDS Biotechnology by 38.4% in the fourth quarter. Marshall Wace LLP now owns 39,024 shares of the company’s stock worth $64,000 after purchasing an additional 10,837 shares during the last quarter. Raymond James Financial Inc. purchased a new position in PDS Biotechnology during the 4th quarter worth $26,000. Jane Street Group LLC acquired a new position in shares of PDS Biotechnology during the fourth quarter valued at about $58,000. Blair William & Co. IL increased its stake in PDS Biotechnology by 29.4% during the 4th quarter. Blair William & Co. IL now owns 157,500 shares of the company’s stock valued at $257,000 after purchasing an additional 35,757 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in shares of PDS Biotechnology by 9.8% in the 3rd quarter. Geode Capital Management LLC now owns 415,113 shares of the company’s stock valued at $1,586,000 after acquiring an additional 37,142 shares during the period. Institutional investors own 26.84% of the company’s stock.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.